X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA PIRAMAL ENTERPRISES PLETHICO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -1.1 36.7 - View Chart
P/BV x 0.0 3.0 0.5% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 PLETHICO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
PIRAMAL ENTERPRISES
Mar-17
PLETHICO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3952,095 18.8%   
Low Rs311,025 3.1%   
Sales per share (Unadj.) Rs604.4492.8 122.6%  
Earnings per share (Unadj.) Rs32.572.6 44.8%  
Cash flow per share (Unadj.) Rs51.394.7 54.2%  
Dividends per share (Unadj.) Rs021.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs473.6862.5 54.9%  
Shares outstanding (eoy) m34.08172.56 19.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.2 11.1%   
Avg P/E ratio x6.621.5 30.5%  
P/CF ratio (eoy) x4.216.5 25.2%  
Price / Book Value ratio x0.51.8 24.9%  
Dividend payout %028.9 0.0%   
Avg Mkt Cap Rs m7,262269,194 2.7%   
No. of employees `000NA4.0 0.0%   
Total wages/salary Rs m1,59617,939 8.9%   
Avg. sales/employee Rs ThNM21,190.3-  
Avg. wages/employee Rs ThNM4,470.1-  
Avg. net profit/employee Rs ThNM3,120.0-  
INCOME DATA
Net Sales Rs m20,59885,037 24.2%  
Other income Rs m3862,338 16.5%   
Total revenues Rs m20,98487,374 24.0%   
Gross profit Rs m2,81834,991 8.1%  
Depreciation Rs m6423,817 16.8%   
Interest Rs m1,59320,310 7.8%   
Profit before tax Rs m96913,202 7.3%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m-1382,281 -6.1%   
Profit after tax Rs m1,10712,520 8.8%  
Gross profit margin %13.741.1 33.2%  
Effective tax rate %-14.317.3 -82.7%   
Net profit margin %5.414.7 36.5%  
BALANCE SHEET DATA
Current assets Rs m18,87787,590 21.6%   
Current liabilities Rs m11,896185,578 6.4%   
Net working cap to sales %33.9-115.2 -29.4%  
Current ratio x1.60.5 336.2%  
Inventory Days Days3631 115.8%  
Debtors Days Days19848 416.1%  
Net fixed assets Rs m9,861108,523 9.1%   
Share capital Rs m341345 98.7%   
"Free" reserves Rs m12,331148,481 8.3%   
Net worth Rs m16,139148,826 10.8%   
Long term debt Rs m4,706144,957 3.2%   
Total assets Rs m33,146482,394 6.9%  
Interest coverage x1.61.7 97.4%   
Debt to equity ratio x0.31.0 29.9%  
Sales to assets ratio x0.60.2 352.5%   
Return on assets %8.16.8 119.7%  
Return on equity %6.98.4 81.5%  
Return on capital %12.312.0 102.8%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40215,001 29.3%   
Fx outflow Rs m3,1845,150 61.8%   
Net fx Rs m1,2199,851 12.4%   
CASH FLOW
From Operations Rs m2,437-100,393 -2.4%  
From Investments Rs m-6,265-24,202 25.9%  
From Financial Activity Rs m2,490135,705 1.8%  
Net Cashflow Rs m-1,33711,110 -12.0%  

Share Holding

Indian Promoters % 82.7 52.9 156.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 4.0 107.5%  
FIIs % 5.5 26.6 20.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 16.5 45.5%  
Shareholders   10,665 93,274 11.4%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS